#61
|
||||
|
||||
Óâàæàåìàÿ ßíà, íå çíàþ êàê ñèòóàöèÿ â NSLIJ, íî â òåõ ìåñòàõ ãäå ìíå óäàëîñü ïîíàáëþäàòü ðàäèîëîãè ñìîòðÿò ÔÎÒÎÃÐÀÔÈÈ, ñäåëàííûå òåõíèêîì, äàæå íå æèâóþ çàïèñü. Ýòî î÷åíü ïëîõî è ïîíÿòíî ïî÷åìó ýòî äåëàåòñÿ (ýêîíîìèÿ äåíåã è âðåìåíè). ß ñàì èìåþ íåêîòîðûé îïûò àáäîìèíàëüíûõ ÓÇÈ èññëåäîâàíèé åùå èç Ðîññèè è ðóòèííî ÷èòàþ ÝÕÎ â ñâîåé ïðàêòèêå è åùå äëÿ ðÿäà îôèñîâ.
1. Èíòåðïðåòèðîâàòü íåïîäâèæíûå êàðòèíêè õîðîøî ÍÅËÜÇß. 2. Èíòåðïðåòèðîâàòü è äåëàòü èññëåäîâàíèå âèäèìî äîæåí îäèí ÷åëîâåê 3. Òåõíè÷åñêîå êà÷åñòâî ñêàíèðîâàíèÿ íåêîòîðûìè ðàäèîëîãàìè íåëüçÿ íàçâàòü óäîâëåòâîðèòåëüíûì. 4. Áîëüøîé ïðîöåíò ÓÇÈ è ÝÕÎ òåõíèêîâ íå èìåþò ïîíÿòèÿ î ìåäèöèíå è íå â ñîñòîÿíèè ìîäèôèöèðîâàòü ïðîòîêîë îáñëåäîâàíèÿ ïî õîäó äåëà. 5. ÓÇÈ ìåòîä â ÑØÀ íå èñïîëüçóåòñÿ íà ïîëíóþ ìîùíîñòü. |
#62
|
||||
|
||||
Öèòàòà:
 îñòàëüíîì, âîçìîæíî, åñòü äîëÿ ïðàâäû. |
#63
|
|||
|
|||
Öèòàòà:
È âñ¸ æå. Îáúÿñíèòå ìíå êàê ìîæíî ïðè ïîìîùè ÓÇÈ âñåãäà ÷¸òêî âûÿâèòü èçìåíåíèÿ ïîäæåëóäî÷íîé æåëåçû â óðãåíòíîé ñèòóàöèè? Íàïîëíåíèå æåëóäêà âîäîé èñêëþ÷àåòñÿ ïî ïîíÿòíîé ïðè÷èíå ðâîòû (à òî è ÄÇ "ïàíêðåàòèò" ìîæíî ïîñòàâèòü ïîä ñîìíåíèå áåç îíîé). Ò.å. òóò áåç ÊÒ "ñêó÷íî". À âîò óæå â ïðîöåññå ëå÷åíèÿ, íàáëþäåíèÿ ïàöèåíòà, äëÿ ñêðèíèíãà (åñëè ìîæíî òàê âûðàçèòüñÿ) èçìåíåíèé â æèâîòå è ï/æ æåëåçå, â óñëîâèÿõ ïîäãîòîâêè ïàöèåíòà, ÓÇÈ ìíå êàæåòñÿ îïðàâäàíî íà âñå 100. Îñîáåííî ïðè îòñóòñòâèè ÊÒ â ðàäèóñå 100 êì. È òîãäà òîæå ìîæíî âûÿâèòü î÷àãè äåñòðóêöèè, ÷òî óæå ÿâëÿåòñÿ ïîêàçàíèåì ê îïåðàöèè. |
#64
|
||||
|
||||
P.S. Êñòàòè ñàìè ðàäèîëîãè íàçûâàþò ÓÇÈ ñàìûì ñëîæíûì äëÿ èíòåðïðåòàöèè èññëåäîâàíèåì â ðàäèîëîãèè.
|
#65
|
||||
|
||||
ÓÇ êàðòèíêà - ýòî òåàòð òåíåé
|
#66
|
||||
|
||||
Öèòàòà:
|
#67
|
||||
|
||||
HIDA óæå ìíîãî ëåò íå èñïîëüçóåòñÿ. Òîëüêî DISIDA and BRIDA. Ïðîáëåìà ñ HIDA ñîñòîÿëà â òîì, ÷òî ñêàíèðîâàíèå áûëî íåâîçìîæíî ïðè âûñîêîì áèëèðóáèíå.
|
#68
|
||||
|
||||
Öèòàòà:
|
#69
|
||||
|
||||
Radiopharmaceuticals
Tc 99m IDA (Iminodiacetic acid) analogs: Tc-iminodiacetic acid derivatives are organic anions. These agents predominantly bind to albumin in the circulation and are carried to the liver. Protein binding helps to decrease renal excretion. Dissociation of the tracer from albumin takes place at the space of Disse and the tracer enters the anion exchange pathway of bilirubin. Since the compounds share the same hepatic uptake and excretion pathways, IDA compounds are subject to competitive inhibition by bilirubin. IDA compounds are taken up by hepatocytes and are NOT conjugated prior to their excretion (they are excreted unchanged). In general, increasing the length of the alkyl chain substitution on the benzene ring of IDA, will increase the biliary excretion of the agent and decrease the renal clearence. This is because substitutions of non-polar groups on the phenyl ring make the molecule more lipophilic and the more lipophilic a compound, the greater its protein binding. (Protein binding prevents renal excretion and promotes hepatic uptake) HIDA: dimethyl 85% excreted by the liver, 15% by the kidneys Good visualization at bili levels of 5-7 mg/dl discontinued DISIDA: diisopropyl (Disofenin) Approximately 88% hepatic excretion, 10% renal Good visualization at bilirubin levels approaching 20 BRIDA: (Mebrofenin) An analog of lidocaine m-3-bromo-trimethyl-IDA, has greatest resistance to displacement by bilirubin. There is about 98% hepatic excretion of the agent. T1/2 of uptake is about 6 minutes, and the T1/2 of excretion is about 14 minutes. |
#70
|
||||
|
||||
Ïî êàêèì ïîêàçàíèÿì Âû èõ ïðèìåíÿåòå?
 õèðóðãèè áèëèðóáèí 20+ âñòðå÷àåòñÿ ðåæå ÷åì â ãåïàòîëîãèè. ß, âèäèìî, äóìàþ ïðî äðóãèå ïîêàçàíèÿ. Âñ¸ ÷òî ìíå íàäî çíàòü - çàêðûò ëè ïðîòîê è äâèæåòñÿ ëè ñòåíêà ïóçûðÿ. |
#71
|
||||
|
||||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#72
|
||||
|
||||
×åñòíî ãîâîðÿ, íå òàê ìíîãî ïîêàçàíèé. HIDA âïåðâûå áûëà ïðèìåíåíà äëÿ äèàãíîñòèêè àòðåçèè ó äåòåé. Ïðî îñòðûé õîëåöèñòèò óæå ãîâîðèëè, çàêóïîðêà õîëåäîõà - òîò æå ïðèíöèï, ýêñòðàâàçàöèÿ æåë÷è - òîæå ïîíÿòíî. Õðîíè÷åñêèå ïðîáëåìû ïðîòîêîâ, è ò.ï.
Ïóíêò À â òîì ñïèñêå - ýòî âñ¸ âûøåñêàçàííîå. Âîò è ïîëó÷àåòñÿ, ïî êðàéíåé ìåðå ó ìåíÿ â áàøêå, ÷òî äëÿ îïðåäåëåíèÿ âñåãî ïåðå÷èñëåííîãî äîñòàòî÷íî ñàìîãî äåø¸âîãî òåñòà. IDA âðåäà áîëüíûì íå íàíîñèò. |
#73
|
||||
|
||||
Öèòàòà:
|
#74
|
||||
|
||||
Öèòàòà:
|
#75
|
|||
|
|||
ÎÊ! Êîãäà ðåøèòåñü ïðîîïåðèðîâàòü,- çâîíèòå! Òðóáî÷êó åìó ïîñòàâèì ( äíÿ íà òðè-÷åòûðå)
|